A rational targeted therapy for platinum-resistant small-cell lung cancer

Benjamin J. Drapkin; John D. Minna

doi:10.1016/j.ccell.2021.03.003

A rational targeted therapy for platinum-resistant small-cell lung cancer

Benjamin J. Drapkin, John D. Minna

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia–mutated and rad3-related) inhibitor berzosertib.

Original language	English (US)
Pages (from-to)	453-456
Number of pages	4
Journal	Cancer Cell
Volume	39
Issue number	4
DOIs	https://doi.org/10.1016/j.ccell.2021.03.003
State	Published - Apr 12 2021

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2021.03.003

Cite this

@article{008fe150ea76419099b302eeeb1c7226,

title = "A rational targeted therapy for platinum-resistant small-cell lung cancer",

abstract = "Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia–mutated and rad3-related) inhibitor berzosertib.",

author = "Drapkin, {Benjamin J.} and Minna, {John D.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = apr,

day = "12",

doi = "10.1016/j.ccell.2021.03.003",

language = "English (US)",

volume = "39",

pages = "453--456",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - A rational targeted therapy for platinum-resistant small-cell lung cancer

AU - Drapkin, Benjamin J.

AU - Minna, John D.

PY - 2021/4/12

Y1 - 2021/4/12

N2 - Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia–mutated and rad3-related) inhibitor berzosertib.

AB - Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia–mutated and rad3-related) inhibitor berzosertib.

UR - http://www.scopus.com/inward/record.url?scp=85103709473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103709473&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.03.003

DO - 10.1016/j.ccell.2021.03.003

M3 - Article

C2 - 33848475

AN - SCOPUS:85103709473

SN - 1535-6108

VL - 39

SP - 453

EP - 456

JO - Cancer Cell

JF - Cancer Cell

IS - 4

ER -

A rational targeted therapy for platinum-resistant small-cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this